Abstract: The preceding article on the use of prostate brachytherapy in men aged <55 years from the Princess Margaret Hospital (PMH) group provides a good opportunity to highlight several attributes of modern prostate brachytherapy that make it an attractive option for the treatment of prostate cancer. Median 5 Year Follow-up of 125Iodine Brachytherapy as Monotherapy in Men Aged ≤ 55 Years With Favorable Prostate CancerUrologyVol. 75Issue 6PreviewTo report the genitourinary (GU) and gastrointestinal (GI) toxicity rates, erectile function preservation, and biochemical outcome (bNED) in men aged ≤ 55 years treated with 125iodine (125I) brachytherapy (BT). Full-Text PDF ReplyUrologyVol. 75Issue 6PreviewThe author has raised a very important point concerning quality assurance in prostate brachytherapy. Implant quality can and should be assessed, and the results monitored on a regular basis. Although we have reported excellent treatment outcomes for younger men, these results were obtained by a team that was both dedicated to quality and capable of consistently performing high-quality brachytherapy. Under these circumstances, brachytherapy would appear to be a viable option that younger men should be given the opportunity to consider when deciding on a treatment. Full-Text PDF
Publication Year: 2010
Publication Date: 2010-06-01
Language: en
Type: editorial
Indexed In: ['crossref', 'pubmed']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot